Johnson & Johnson (JNJ) Stake Increased by Parametrica Management Ltd

Parametrica Management Ltd grew its holdings in Johnson & Johnson (NYSE:JNJ) by 21.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,597 shares of the company’s stock after buying an additional 465 shares during the period. Parametrica Management Ltd’s holdings in Johnson & Johnson were worth $344,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Lenox Wealth Advisors Inc. lifted its position in shares of Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after buying an additional 5 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Johnson & Johnson by 241.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after buying an additional 841 shares during the last quarter. Ullmann Financial Group Inc. acquired a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $186,000. Taylor Wealth Management Partners lifted its position in shares of Johnson & Johnson by 19.8% in the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after buying an additional 250 shares during the last quarter. Finally, Puplava Financial Services Inc. acquired a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $202,000. 65.90% of the stock is owned by institutional investors.

In other news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by company insiders.

Johnson & Johnson (NYSE JNJ) traded up 0.13% during midday trading on Thursday, hitting $136.83. The company had a trading volume of 2,798,292 shares. The firm has a market capitalization of $367.25 billion, a P/E ratio of 23.15 and a beta of 0.78. The firm’s 50 day moving average is $132.32 and its 200-day moving average is $130.07. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.52.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. During the same period last year, the firm earned $1.74 earnings per share. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. On average, equities research analysts expect that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were paid a dividend of $0.84 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.46%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 56.76%.

COPYRIGHT VIOLATION NOTICE: “Johnson & Johnson (JNJ) Stake Increased by Parametrica Management Ltd” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/2955757/johnson-johnson-jnj-stake-increased-by-parametrica-management-ltd.html.

A number of research firms have recently issued reports on JNJ. Atlantic Securities cut Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price objective for the company. in a research report on Friday, July 21st. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Friday, July 21st. BTIG Research cut Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 price objective for the company. in a research report on Friday, July 21st. Alembic Global Advisors cut Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research report on Friday, July 21st. Finally, Vetr cut Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price objective for the company. in a research report on Monday, September 18th. Five analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $136.02.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.